CASI (NASDAQ: CASI) director He Wei-Wu details share and option stakes

Rhea-AI Filing Summary

CASI Pharmaceuticals director and over-10% holder Dr. Wei-Wu He has filed a Form 3 reporting his existing stakes in the company. He reports direct ownership of 1,910,550 Ordinary Shares and several option awards to buy additional Ordinary Shares at an exercise price of $1.93 with expirations between 2031 and 2033.

He also reports multiple indirect holdings of Ordinary Shares through entities such as Emerging Technology Partners, ETP funds, HE Family GRAT and the Huiying Memorial Foundation, and specifically disclaims beneficial ownership of shares held by the Foundation.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

He Wei-Wu

(Last) (First) (Middle)

1701-1702, CHINA CENTRAL OFFICE TOWER 1,

NO. 81 JIANGUO ROAD CHAOYANG DISTRICT

(Street)

BEIJING 100025

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CASI Pharmaceuticals, Inc. [ CASIF ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Share	1,910,550	D
Ordinary Share	44,107	I	See Footnote(1)
Ordinary Share	753,234	I	See Footnote(2)
Ordinary Share	300,000	I	See Footnote(3)
Ordinary Share	100,000	I	See Footnote(4)
Ordinary Share	637,644	I	See Footnote(5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Note (right to convert)	03/28/2026	12/26/2028	Ordinary Share	(6)	(6)	I	See Footnote(7)
Convertible Note (right to convert)	04/10/2026	01/08/2029	Ordinary Share	(6)	(6)	I	See Footnote(7)
Convertible Note (right to convert)	05/21/2026	02/18/2029	Ordinary Share	(6)	(6)	I	See Footnote(7)
Option (right to buy)	05/12/2025	05/12/2033	Ordinary Share	20,000	$1.93	D
Option (right to buy)	05/12/2026	05/12/2033	Ordinary Share	20,000	$1.93	D
Option (right to buy)	04/14/2023	04/27/2031	Ordinary Share	100,000	$1.93	D
Option (right to buy)	04/27/2025	04/27/2031	Ordinary Share	100,000	$1.93	D
Option (right to buy)	(8)	04/27/2031	Ordinary Share	300,000	$1.93	D

Explanation of Responses:

1. Held by Emerging Technology Partners, LLC, a Delaware limited liability company, of which Dr. He is founder and managing partner.

2. Held by ETP Global Fund. L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.

3. Held by ETP BioHealth III Fund, L.P., a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.

4. Held by HE Family GRAT, a grantor retained annuity trust organized under the law of Nevada for the benefit of Dr. Wei-Wu He's family members, and Dr. Wei-Wu He is the trustee of HE Family GRAT.

5. Held by Huiying Memorial Foundation, a 501(c)(3) private family foundation under the law of Delaware and Dr. He is a member of the board of trustees and an officer of the Huiying Memorial Foundation. Dr. He does not participate in the investment decisions of the Foundation with respect to CASI's ordinary shares and disclaims beneficial ownership of CASI's ordinary shares held by Huiying Memorial Foundation.

6. The conversion price is volume weighted average closing price of the issuer's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global Fund III L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. Pursuant to the trading price of the issuer's ordinary shares as of March 17, 2026, the amount of ordinary shares convertible under each Note is 5,000,000 (without considering accrued but unpaid interest).

7. Held by ETP Global Fund III L.P., , a Delaware limited partnership, of which Emerging Technology Partners, LLC is the general partner.

8. Performance based options granted and exercisable upon achievement.

	/s/ Wei-Wu He	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Dr. Wei-Wu He’s Form 3 for CASI (CASI) disclose?

The Form 3 shows Dr. Wei-Wu He’s existing ownership in CASI. It lists 1,910,550 Ordinary Shares held directly, multiple option awards exercisable at $1.93 per share, and several indirect holdings through funds and family entities, including a foundation where he disclaims beneficial ownership.

How many CASI Ordinary Shares does Dr. He hold directly on this Form 3?

Dr. He reports direct ownership of 1,910,550 CASI Ordinary Shares. This figure reflects only his personal direct holdings, separate from additional positions reported as indirect interests through investment funds, a family trust and a charitable foundation associated with him.

What stock options in CASI does Dr. Wei-Wu He report on the Form 3?

He reports several option grants over CASI Ordinary Shares with an exercise price of $1.93 and expirations extending to 2031 and 2033. These options give him the right to buy additional shares, including grants over 300,000 and 100,000 underlying shares each.

What indirect CASI holdings are reported for Dr. Wei-Wu He?

Indirect holdings are reported through Emerging Technology Partners, ETP funds, HE Family GRAT and the Huiying Memorial Foundation. The filing notes these entities hold CASI Ordinary Shares, and it clarifies that Dr. He disclaims beneficial ownership of shares held by the Huiying Memorial Foundation.

Does Dr. Wei-Wu He hold any CASI convertible notes on this Form 3?

The filing lists several “Convertible Note (right to convert)” positions tied to CASI Ordinary Shares, held indirectly. A footnote explains the conversion price is based on a volume-weighted average, with a band between $1 and $2 per Ordinary Share for each note.

What does the footnote say about CASI note conversion into Ordinary Shares?

A footnote states each note’s conversion price is the volume-weighted average closing price over five days, capped between $1 and $2 per share. Based on CASI’s trading price on March 17, 2026, each note was then convertible into 5,000,000 Ordinary Shares.